Gilead’s HIV drugs generated $20.8bn in full-year 2025 sales, up 6% from 2024. This was mainly fuelled by the company’s ...
By Deena Beasley Feb 10 (Reuters) - Gilead Sciences on Tuesday issued a 2026 financial forecast that was at the low end of analysts' expectations, including sales of its pioneering twice-yearly HIV ...
In the early 1960s, after studies confirmed that it was linked to congenital disorders in more than 10,000 children, ...
Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.
Guidance for HIV sales growth increased to approximately 6% for 2026, up from prior expectations, while Yeztugo's revenue ...
Gilead Sciences Inc. forecast 2026 product revenue and profit that missed analysts’ expectations, even after it outperformed ...
Quarterly sales of HIV prevention drug Yeztugo, which was launched in the U.S. last year as a twice-yearly injection, totaled $96 million, beating the $88 million forecast by Wall Street, according ...
Harley Ransom began practicing harm reduction in southeastern Ontario in the late 1980s, when he was 6 years old. His ...
BETHLEHEM, Pa. - The product that put OraSure on the map more than two decades ago is expanding its reach. On Tuesday the ...
By Sydney Byerly The Indiana Citizen February 9, 2026 A conservative split over syringe exchanges is resurfacing this year, ...
One in nine people in prisons globally have a history of injecting drug use and their risk of HIV, viral hepatitis and tuberculosis is up to 45 times higher than in the general population. Yet access ...
Frank discussions around sex, pleasure, trans solidarity, and improved medical care could all help ease HIV's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results